Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS (TAURUS)
CODICE STUDIO
NCT06189833
TIPOLOGIA
Prima linea giovani
NOME SPONSOR
European Myeloma Network
DESCRIZIONE
Trattamento
Experimental: D-VRd + ASCT + DVRD
Participants will receive daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRD) for 4 induction cycles prior to and 2 consolidation cycles following autologous stem cell transplantation.
Daratumumab subcutaneously (SC), 1800 mg on days 1, 8, 15, and 22 of cycle 1 and 2, on days 1 and 15 of cycle 3-6. Bortezomib SC 1.3mg/m2 on days 1, 8, 15, 22 of cycle 1-6. Lenalidomide orally 25 mg once daily on days 1-21 of cycle 1-6. Dexamethasone 20 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 of cycle 1-6.
FARMACI UTILIZZATI